Abstract
Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer. PBSCs were collected from 17 patients with breast (n = 11), ovarian (n = 5), and gastric (n = 1) cancer after administration of Taxol (170 mg/m2 x 1) and CY (4 g/m2 x 1) followed by rhG-CSF (10 micrograms/kg/d). PBSC collections after Taxol and CY were compared with PBSC collections from nine patients with stage IV breast (n = 8) or stage III ovarian (n = 1) cancer who had received CY (4 g/m2 x 1) followed by rhG-CSF (16 micrograms/kg/d) for mobilization. Mean WBC and platelet counts on the first day of apheresis were 6.3 x 10(9)/L (range, 1.9 to 22.1) and 35 x 10(9)/L (range, 19 to 77), respectively. The median numbers of CD34+ cells, peripheral-blood mononuclear cells (PBMNC), and peripheral-blood total nucleated cells (PBTNC) collected were 13.02 x 10(6)/kg (range, 5.4 to 57.8; mean, 16.02), 6.86 x 10(8)/kg (range, 1.9 to 51.2), and 17.41 x 10(8)/kg (range, 2.4 to 106.6), respectively. In the comparison group, the media...Continue Reading
Citations
Jan 1, 1997·Vox Sanguinis·G MenichellaB Bizzi
Aug 26, 1998·American Journal of Clinical Oncology·C H WeaverC D Buckner
Dec 19, 1998·British Journal of Haematology·A YounesF Cabanillas
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H. KurataK. Tanaka
Jun 25, 2002·Bone Marrow Transplantation·T DemirerH Akan
Jan 2, 2004·Breast Cancer Research and Treatment·Alberto BallestreroFranco Patrone
Apr 21, 2004·Annals of Plastic Surgery·Jeffrey S IsenbergJohn O Ojeifo
Sep 30, 2000·Stem Cells·R K ShadduckJ Lister
Jun 1, 1999·Journal of Hematotherapy·T DemirerC D Buckner
May 7, 2003·Bone Marrow Transplantation·T DemirerH Akan
Jun 14, 2003·Journal of Hematotherapy & Stem Cell Research·John O OjeifoKenneth R Meehan
Dec 14, 2002·Drugs·Paolo Anderlini, Richard Champlin
May 23, 1998·Journal of Hematotherapy·L S SchwartzbergC D Buckner
Jan 1, 1996·Stem Cells·T DemirerW I Bensinger
Jun 13, 2000·Bone Marrow Transplantation·M L DonatoR E Champlin
Feb 27, 2001·Bone Marrow Transplantation·M A DíazF Deméocq
Apr 4, 2000·Bone Marrow Transplantation·T DemirerH Koç
Jun 1, 1999·Journal of Hematotherapy·M de Magalhaes-SilvermanE Ball
Jan 10, 2002·Bone Marrow Transplantation·Y NietoP A McSweeney
Dec 18, 2001·Journal of Clinical Apheresis·T DemirerH Koç
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Kenneth R MeehanMarc E Lippman
May 14, 2005·Journal of Clinical Apheresis·Hyun-Jung ChoDae-Won Kim
Nov 9, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Taner DemirerHamdi Akan
Jul 12, 2003·Blood·David G MaloneyRainer Storb
Oct 6, 2017·Journal of Clinical Apheresis·Ugur Sahin, Taner Demirer
Feb 16, 2000·Bone Marrow Transplantation·J Gómez-EspuchV Vicente
Aug 18, 2001·Bone Marrow Transplantation·S BilgramiP J Tutschka
May 26, 1998·Environmental Health Perspectives·R E Parchment
Feb 16, 2000·Bone Marrow Transplantation·S BilgramiP J Tutschka
May 22, 2001·Bone Marrow Transplantation·G G LaportS F Williams
Jul 15, 2003·Bone Marrow Transplantation·U De GiorgiM Marangolo